Breast Cancer News

Breast Cancer News

Pentagon Study Finds Higher Cancer Rates Among Pilots, Ground Crews

Publish Date March 23, 2023

Military pilots and the ground crews who fuel and maintain their aircraft have higher rates of certain cancers, a new study shows.

Adverse Birth Outcomes More Common Among AYAs With Cancer During Pregnancy

Publish Date March 22, 2023

Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.

Discrimination Tied to Frailty in African-American Cancer Survivors

Publish Date March 22, 2023

Among African-American cancer survivors, experiencing discrimination is associated with frailty, a study suggests.

Low-Dose Tamoxifen Reduces Risk of Breast Cancer Long-Term

Publish Date March 21, 2023

Low-dose tamoxifen reduces the risk of breast cancer among patients with intraepithelial neoplasia for several years, data suggest.

Clinical Trial: Adding Vorinostat to Pembrolizumab and Tamoxifen in ER+ Breast Cancer

Publish Date March 20, 2023

Researchers are conducting a phase 2 trial to test pembrolizumab and tamoxifen, with or without vorinostat, in patients with ER+ breast cancer.

Clinical Trial: Valemetostat Plus Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer

Publish Date March 20, 2023

Researchers are testing valemetostat plus trastuzumab deruxtecan in patients with HER2-low/ultra-low/null metastatic breast cancer.

Clinical Trial: Tucatinib Plus Alpelisib in PIK3CA-Mutant, HER2+ Breast Cancer

Publish Date March 20, 2023

Researchers are conducting a phase 1b/2 trial to test tucatinib plus alpelisib in patients with advanced, PIK3CA-mutant, HER2+ breast cancer.

Clinical Trial: CAR-T Cells in Mesothelin-Expressing Triple-Negative Breast Cancer

Publish Date March 20, 2023

Researchers are conducting a phase 1 trial to test CAR T-cell therapy in patients with mesothelin-expressing triple-negative breast cancer.

Robust Breast Cancer Patients Have Higher Risk of Worsening Frailty Status 

Publish Date March 17, 2023

Non-frail patients with early-stage breast cancer have an increased risk of worsening frailty status after locoregional therapy, a study suggests.

Axillary Lymphadenopathy Resolves at Mean 102 Days After COVID-19 Booster

Publish Date March 16, 2023

The mean time to resolution of axillary lymphadenopathy after a COVID-19 vaccine booster is 102 days, according to a study.

10-Year Data Support Use of Adjuvant Paclitaxel-Trastuzumab in HER2+ Breast Cancer

Publish Date March 14, 2023

Updated results support the use of adjuvant paclitaxel and trastuzumab in small, node-negative, HER2-positive breast cancer, according to researchers.

Alisertib Does Not Restore Sensitivity to Fulvestrant in Endocrine-Resistant Breast Cancer

Publish Date March 13, 2023

Alisertib monotherapy has shown activity in postmenopausal patients with endocrine-resistant, HER2-negative, metastatic breast cancer, but it was not able to restore sensitivity to fulvestrant in this patient population.

Women With BRCA1/2 Mutations Have High Risk of Cancer After Age 50

Publish Date March 10, 2023

The risk of cancer remains high for women older than 50 years with BRCA1 or BRCA2 mutations, a study suggests.

FDA Says Mammography Reports Need to Include Breast Density Information

Publish Date March 10, 2023

Updated regulations require mammography facilities to notify patients about the density of their breasts.

COVID-19 Sequelae in Cancer by Vaccination Status and Variant Era

Publish Date March 9, 2023

COVID-19 vaccination may reduce the risk of COVID-19 sequelae in patients with cancer, according to researchers.

Disparities in TNBC Incidence Vary Across States

Publish Date March 8, 2023

TNBC incidence rates ranged from less than 7 per 100,000 among Asian and Pacific Islander patients to more than 29 per 100,000 among Black patients.

Anatomic Stage, Receptor Status Influence Timing of Breast Cancer Recurrence

Publish Date March 7, 2023

Anatomic stage and receptor status influence the timing of recurrence for patients with local-regional breast cancer, a study suggests.

FDA Expands Breast Cancer Indications for Verzenio

Publish Date March 7, 2023

The FDA has expanded the approval of Verzenio (abemaciclib) plus endocrine therapy, removing the Ki-67 score requirement for patient selection.

HER2-Low Breast Cancer Not a Unique Biological Entity, Researchers Say

Publish Date March 6, 2023

There are “minimal prognostic differences” between HER2-low breast cancer and HER2-negative breast cancer, according to researchers.

Artificial Intelligence Can Predict Cancer Survival Using Data From a Single Consultation

Publish Date March 6, 2023

Artificial intelligence can predict survival in cancer patients using information from a patient’s initial consultation with an oncologist, a study suggests.